Logo image of TNGX

TANGO THERAPEUTICS INC (TNGX) Stock Fundamental Analysis

USA - NASDAQ:TNGX - US87583X1090 - Common Stock

7.495 USD
-0.04 (-0.46%)
Last: 10/24/2025, 8:00:01 PM
7.7 USD
+0.21 (+2.74%)
Pre-Market: 10/27/2025, 5:00:32 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TNGX. TNGX was compared to 534 industry peers in the Biotechnology industry. TNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TNGX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TNGX has reported negative net income.
TNGX had a negative operating cash flow in the past year.
In the past 5 years TNGX always reported negative net income.
TNGX had a negative operating cash flow in each of the past 5 years.
TNGX Yearly Net Income VS EBIT VS OCF VS FCFTNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

TNGX has a Return On Assets (-61.19%) which is in line with its industry peers.
The Return On Equity of TNGX (-107.86%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -61.19%
ROE -107.86%
ROIC N/A
ROA(3y)-30.42%
ROA(5y)-20.6%
ROE(3y)-49.57%
ROE(5y)-33.14%
ROIC(3y)N/A
ROIC(5y)N/A
TNGX Yearly ROA, ROE, ROICTNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TNGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNGX Yearly Profit, Operating, Gross MarginsTNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNGX has been increased compared to 1 year ago.
There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNGX Yearly Shares OutstandingTNGX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TNGX Yearly Total Debt VS Total AssetsTNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

TNGX has an Altman-Z score of 0.12. This is a bad value and indicates that TNGX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.12, TNGX perfoms like the industry average, outperforming 58.99% of the companies in the same industry.
TNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.12
ROIC/WACCN/A
WACC8.66%
TNGX Yearly LT Debt VS Equity VS FCFTNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.75 indicates that TNGX has no problem at all paying its short term obligations.
With a Current ratio value of 4.75, TNGX perfoms like the industry average, outperforming 52.06% of the companies in the same industry.
TNGX has a Quick Ratio of 4.75. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
TNGX has a Quick ratio (4.75) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.75
Quick Ratio 4.75
TNGX Yearly Current Assets VS Current LiabilitesTNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for TNGX have decreased strongly by -16.67% in the last year.
The Revenue for TNGX has decreased by -42.84% in the past year. This is quite bad
The Revenue has been growing slightly by 4.34% on average over the past years.
EPS 1Y (TTM)-16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-45.83%
Revenue 1Y (TTM)-42.84%
Revenue growth 3Y4.34%
Revenue growth 5YN/A
Sales Q2Q%-83.99%

3.2 Future

The Earnings Per Share is expected to grow by 10.05% on average over the next years. This is quite good.
Based on estimates for the next years, TNGX will show a very strong growth in Revenue. The Revenue will grow by 40.69% on average per year.
EPS Next Y7.39%
EPS Next 2Y-8.53%
EPS Next 3Y-7.53%
EPS Next 5Y10.05%
Revenue Next Year8.58%
Revenue Next 2Y-38.75%
Revenue Next 3Y-22.25%
Revenue Next 5Y40.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TNGX Yearly Revenue VS EstimatesTNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
TNGX Yearly EPS VS EstimatesTNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNGX. In the last year negative earnings were reported.
Also next year TNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNGX Price Earnings VS Forward Price EarningsTNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNGX Per share dataTNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

TNGX's earnings are expected to decrease with -7.53% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.53%
EPS Next 3Y-7.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TANGO THERAPEUTICS INC

NASDAQ:TNGX (10/24/2025, 8:00:01 PM)

Premarket: 7.7 +0.21 (+2.74%)

7.495

-0.04 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners108.56%
Inst Owner Change0%
Ins Owners1.53%
Ins Owner Change-7.69%
Market Cap833.89M
Revenue(TTM)24.30M
Net Income(TTM)-145566000
Analysts86.67
Price Target11.09 (47.97%)
Short Float %32.33%
Short Ratio12.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.26%
Min EPS beat(2)-0.84%
Max EPS beat(2)1.36%
EPS beat(4)2
Avg EPS beat(4)6.79%
Min EPS beat(4)-1.28%
Max EPS beat(4)27.91%
EPS beat(8)4
Avg EPS beat(8)8.87%
EPS beat(12)7
Avg EPS beat(12)10.28%
EPS beat(16)10
Avg EPS beat(16)9.26%
Revenue beat(2)0
Avg Revenue beat(2)-37.17%
Min Revenue beat(2)-53.3%
Max Revenue beat(2)-21.03%
Revenue beat(4)1
Avg Revenue beat(4)-19.16%
Min Revenue beat(4)-53.3%
Max Revenue beat(4)45.73%
Revenue beat(8)3
Avg Revenue beat(8)11.17%
Revenue beat(12)5
Avg Revenue beat(12)16.64%
Revenue beat(16)6
Avg Revenue beat(16)11.78%
PT rev (1m)0%
PT rev (3m)8.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)84.87%
EPS NY rev (1m)0%
EPS NY rev (3m)18.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)451.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)74.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.32
P/FCF N/A
P/OCF N/A
P/B 6.18
P/tB 6.18
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.22
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.19%
ROE -107.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.42%
ROA(5y)-20.6%
ROE(3y)-49.57%
ROE(5y)-33.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.56%
Cap/Sales 3.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.75
Quick Ratio 4.75
Altman-Z 0.12
F-Score1
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)190.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.3%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-45.83%
EPS Next Y7.39%
EPS Next 2Y-8.53%
EPS Next 3Y-7.53%
EPS Next 5Y10.05%
Revenue 1Y (TTM)-42.84%
Revenue growth 3Y4.34%
Revenue growth 5YN/A
Sales Q2Q%-83.99%
Revenue Next Year8.58%
Revenue Next 2Y-38.75%
Revenue Next 3Y-22.25%
Revenue Next 5Y40.69%
EBIT growth 1Y-18.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.65%
OCF growth 3YN/A
OCF growth 5YN/A

TANGO THERAPEUTICS INC / TNGX FAQ

What is the ChartMill fundamental rating of TANGO THERAPEUTICS INC (TNGX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TNGX.


What is the valuation status for TNGX stock?

ChartMill assigns a valuation rating of 0 / 10 to TANGO THERAPEUTICS INC (TNGX). This can be considered as Overvalued.


What is the profitability of TNGX stock?

TANGO THERAPEUTICS INC (TNGX) has a profitability rating of 1 / 10.


Can you provide the financial health for TNGX stock?

The financial health rating of TANGO THERAPEUTICS INC (TNGX) is 6 / 10.


Can you provide the expected EPS growth for TNGX stock?

The Earnings per Share (EPS) of TANGO THERAPEUTICS INC (TNGX) is expected to grow by 7.39% in the next year.